AIDS 2026: Long-Acting Weekly Oral HIV Therapy Advances Toward Regulatory Review
Gilead Sciences and Merck reported positive phase 3 trial results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. The ISLEND-1 and ISLEND-2 trials showed the regimen maintained virologic suppression comparable to daily treatments, with 0% and 0.3% of participants having HIV-1 RNA levels above 50 copies/mL, respectively. The companies plan to submit these findings for regulatory review.
How this was made
The 30-second read
Why it matters
The data represent a breakthrough in HIV treatment, offering a weekly oral alternative that could capture market share from daily pills and injectables.
Market read
First disclosure of pivotal HIV trial data; likely to move GILD and MRK stocks and influence the broader HIV therapeutic landscape.
What to watch
competition from injectable long‑acting therapies and pricing negotiations with payors
Background
Phase 3 ISLEND‑1 and ISLEND‑2 trials showed non‑inferior virologic suppression versus daily regimens, with higher patient satisfaction.
Ticker impact
Gilead Sciences announced positive Phase 3 data for the once‑weekly islatravir/lenacapavir regimen presented at AIDS 2026.
potential upside of 5‑10% on near‑term news flow
First disclosure of pivotal data, high clinical relevance and regulatory filing plans.
Merck co‑presented the same Phase 3 data for the investigational weekly HIV regimen at the conference.
potential upside of 3‑7% as market prices in the data.
First report of Merck‑partnered trial results, indicating a novel oral long‑acting HIV option.
Market effects
could spur further investment in oral long‑acting antivirals across the biotech sector
strengthens US biotech exposure; may influence Latin American HIV treatment markets
first oral weekly HIV regimen globally, potential worldwide demand
Counterpoint
if regulatory hurdles delay approval, the short‑term rally may be limited
Key entities
- companyGilead Sciences
US biotech firm co‑developing the weekly HIV regimen
- companyMerck
US pharmaceutical company co‑developing the regimen
- organizationInternational AIDS Society
Host of the AIDS 2026 conference where data were presented
